Back to Nephrology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Renal Anemia

Overview

Spherix’s coverage of the dynamic renal anemia market monitors and closely tracks the evolving landscape of anemia of CKD treatments, including iron (oral and IV), ESAs, and upcoming (and highly anticipated) new HIF-PH inhibitors. Quarterly tracking, monthly pulses on new launches, and deep dives into patient date position Spherix uniquely as experts in this market.

Services Available

Trending market evolution

  • Renal Anemia (US) - quarterly, n=200

Exploring the patient journey

  • Renal Anemia in CKD Non-Dialysis (US) - annual, n=1,000 patient charts

  • Renal Anemia in Dialysis (US) - annual, n=1,000 patient charts

  • Renal Anemia in Incident Dialysis (US) - annual, n=1,000 patient charts

Benchmarking new brand performance

  • Roxadustat (FibroGen/AstraZeneca/Astellas) in Anemia*

  • Vadadustat (Akebia/Otsuka) in Anemia*

*Pending approvals and launch

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Renal Anemia Coverage